FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367187074> ?p ?o ?g. }

• W4367187074 endingPage "493" @default.
• W4367187074 startingPage "485" @default.
• W4367187074 abstract "Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding. Indobufen is used as an alternative antiplatelet agent in some countries, despite an absence of large-scale clinical trials for this indication. We tested the hypothesis that indobufen is non-inferior to aspirin in reducing the risk of new stroke at 90 days in patients with moderate-to-severe ischaemic stroke.We conducted a randomised, double-blind, double-dummy, active control, non-inferiority trial at 163 tertiary and district general hospitals in China. Eligible participants were aged 18-80 years with acute moderate-to-severe ischaemic stroke (National Institutes of Health Stroke Scale score 4-18). We randomly assigned (1:1) participants within 72 h of the onset of symptoms to receive either indobufen (100 mg tablet twice per day) or aspirin (100 mg tablet once per day) for 90 days. The randomisation sequence was computer generated centrally and stratified by local participating centres. Masked local investigators assigned the random code to patients in ascending order and provided a treatment kit corresponding to the random code. The primary efficacy outcome was new stroke and the primary safety outcome was severe or moderate bleeding, both within 90 days. This primary efficacy outcome was assessed in all randomly assigned and consenting patients and in a per-protocol group (ie, all patients finishing the treatment without major violation of the trial protocol). Safety analyses were done in the safety-analysis population (ie, all patients who received at least one dose of the study drug and had a safety assessment available). We assessed the non-inferiority of indobufen versus aspirin using the one-sided upper limit of the 95% CI of the hazard ratio (HR) with a prespecified non-inferiority margin of 1·25. This trial is registered with ClinicalTrials.gov (NCT03871517).This trial took place between June 2, 2019, and Nov 28, 2021. Of 84 093 patients screened, 5438 patients were randomly assigned to receive either indobufen (n=2715) or aspirin (n=2723), all of whom were included in the primary analyses. Median age was 64·2 years (IQR 56·1-70·6); 1921 (35·3%) were women and 3517 (64·7%) were men. Stroke occurred within 90 days in 213 (7·9%) patients in the indobufen group versus 175 (6·4%) in the aspirin group (HR 1·23, 95% CI 1·01-1·50; pnon-inferiority=0·44). Moderate or severe bleeding occurred in 18 (0·7%) patients in the indobufen group and in 28 (1·0%) in the aspirin group (0·63, 95% CI 0·35 to 1·15; p=0·13). Adverse events within 90 days occurred in 666 (24·5%) patients in the indobufen group and 679 (24·9%) patients in the aspirin group (p=0·73).In patients with acute moderate-to-severe ischaemic stroke, indobufen was not non-inferior to aspirin because the upper limit of the 95% CI was greater than 1·25. Furthermore, indobufen seemed to be inferior to aspirin in reducing the risk of recurrent stroke at 90 days because the lower limit of the 95% CI was greater than 1·00. Although moderate or severe bleeding did not differ between groups, these findings do not support the use of indobufen for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke.Hangzhou Zhongmei Huadong Pharmaceutical and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences.For the Chinese translation of the abstract see Supplementary Materials section." @default.
• W4367187074 created "2023-04-28" @default.
• W4367187074 creator A5000333335 @default.
• W4367187074 creator A5001594817 @default.
• W4367187074 creator A5002946080 @default.
• W4367187074 creator A5003842699 @default.
• W4367187074 creator A5003869199 @default.
• W4367187074 creator A5004317142 @default.
• W4367187074 creator A5005303316 @default.
• W4367187074 creator A5006698828 @default.
• W4367187074 creator A5006804382 @default.
• W4367187074 creator A5008011472 @default.
• W4367187074 creator A5008565642 @default.
• W4367187074 creator A5008742216 @default.
• W4367187074 creator A5009133834 @default.
• W4367187074 creator A5011473033 @default.
• W4367187074 creator A5011656818 @default.
• W4367187074 creator A5011995502 @default.
• W4367187074 creator A5013453267 @default.
• W4367187074 creator A5013989297 @default.
• W4367187074 creator A5014260923 @default.
• W4367187074 creator A5015463546 @default.
• W4367187074 creator A5016010967 @default.
• W4367187074 creator A5016818514 @default.
• W4367187074 creator A5016855459 @default.
• W4367187074 creator A5017941291 @default.
• W4367187074 creator A5019387383 @default.
• W4367187074 creator A5019560977 @default.
• W4367187074 creator A5020564835 @default.
• W4367187074 creator A5020619985 @default.
• W4367187074 creator A5021212748 @default.
• W4367187074 creator A5021809579 @default.
• W4367187074 creator A5022098811 @default.
• W4367187074 creator A5022188084 @default.
• W4367187074 creator A5022237643 @default.
• W4367187074 creator A5022585660 @default.
• W4367187074 creator A5023129885 @default.
• W4367187074 creator A5023547729 @default.
• W4367187074 creator A5024094461 @default.
• W4367187074 creator A5024326471 @default.
• W4367187074 creator A5024442284 @default.
• W4367187074 creator A5024461493 @default.
• W4367187074 creator A5024994180 @default.
• W4367187074 creator A5025303085 @default.
• W4367187074 creator A5025851882 @default.
• W4367187074 creator A5026733694 @default.
• W4367187074 creator A5027240571 @default.
• W4367187074 creator A5027821792 @default.
• W4367187074 creator A5028724670 @default.
• W4367187074 creator A5028875162 @default.
• W4367187074 creator A5029924860 @default.
• W4367187074 creator A5030968272 @default.
• W4367187074 creator A5031711915 @default.
• W4367187074 creator A5032476526 @default.
• W4367187074 creator A5032503755 @default.
• W4367187074 creator A5032665638 @default.
• W4367187074 creator A5032748496 @default.
• W4367187074 creator A5033080900 @default.
• W4367187074 creator A5034235721 @default.
• W4367187074 creator A5034725449 @default.
• W4367187074 creator A5034773911 @default.
• W4367187074 creator A5034995105 @default.
• W4367187074 creator A5035113192 @default.
• W4367187074 creator A5036130651 @default.
• W4367187074 creator A5037090796 @default.
• W4367187074 creator A5038251955 @default.
• W4367187074 creator A5038558223 @default.
• W4367187074 creator A5038967158 @default.
• W4367187074 creator A5039217080 @default.
• W4367187074 creator A5040002054 @default.
• W4367187074 creator A5040957908 @default.
• W4367187074 creator A5041358993 @default.
• W4367187074 creator A5041930591 @default.
• W4367187074 creator A5042567294 @default.
• W4367187074 creator A5042610969 @default.
• W4367187074 creator A5043058022 @default.
• W4367187074 creator A5043388026 @default.
• W4367187074 creator A5044534167 @default.
• W4367187074 creator A5045160919 @default.
• W4367187074 creator A5046225712 @default.
• W4367187074 creator A5046380471 @default.
• W4367187074 creator A5046546698 @default.
• W4367187074 creator A5046732096 @default.
• W4367187074 creator A5046891366 @default.
• W4367187074 creator A5048618875 @default.
• W4367187074 creator A5048686395 @default.
• W4367187074 creator A5048826252 @default.
• W4367187074 creator A5048940582 @default.
• W4367187074 creator A5049716052 @default.
• W4367187074 creator A5049780713 @default.
• W4367187074 creator A5050120592 @default.
• W4367187074 creator A5050566348 @default.
• W4367187074 creator A5050875699 @default.
• W4367187074 creator A5051252569 @default.
• W4367187074 creator A5051622270 @default.
• W4367187074 creator A5051993838 @default.
• W4367187074 creator A5052286157 @default.
• W4367187074 creator A5052748200 @default.

• next